Targacept Inc has recently announced that it will not proceed with its Alzheimer’s drug trial because of apparent mid-stage trial failures. The reasons seem to be that it doesn’t exhibit an edge over standard Alzheimer medication which has had a significant impact on the company’s shares sending them down as much as 19.8 percent.lzheimer Drug Trials
Targacept Chief Executive Stephen Hill is reported to have said that the company no longer intends to invest in further development of TC-1734 (the Alzheimer drug).
TC-1734 was also being tested against Pfizer’s donepezil had previously also failed a mid-stage trial conducted by Targacept’s partners AstaZeneca Plc.
This new failure has had a devastating effect on Targacept, and is downright depressive for patients experiencing Alzheimer’s who were in hope of a better drug.